Expression of cyclo-oxygenase 1 and 2, prostaglandin E synthase and transforming growth factor β1, and their relationship with vascular endothelial growth factors A and C, in primary adenocarcinoma of the small intestine

British Journal of Surgery

Volumn 93, Issue 11, 2006, Pages 1424-1432

  Von Rahden, B H A ^a,c   Brucher B L D M ^a   Langner, C ^b   Siewert, J R ^a   Stein, H J ^a   Sarbia, M ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; MESSENGER RNA; PROSTAGLANDIN E; PROSTAGLANDIN H2 E ISOMERASE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN C;

ADENOCARCINOMA; ADULT; ARTICLE; CANCER SURVIVAL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMALL INTESTINE DISEASE;

ADENOCARCINOMA; AGED; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; FEMALE; GENE EXPRESSION; HUMANS; ILEAL NEOPLASMS; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASM PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RNA, MESSENGER; SURVIVAL ANALYSIS; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 33750948995     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.5426     Document Type: Article

References (39)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5-26.
2. Neugut AI, Jacobson JS, Suh S, Mukherjee R, Arber N. The epidemiology of cancer of the small bowel. Cancer Epidemiol Biomarkers Prev 1998; 7: 243-251.
3. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999; 18: 7908-7916.
4. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002; 94: 252-266.
5. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93: 705-716.
6. Zimmermann KC, Sarbia M, Weber AA, Borchard F, Gabbert HE, Schror K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999; 59: 198-204.
7. Tatsuguchi A, Matsui K, Shinji Y, Gudis K, Tsukui T, Kishida T et al. Cyclooxygenase-2 expression correlates with angiogenesis and apoptosis in gastric cancer tissue. Hum Pathol 2004; 35: 488-495.
8. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroentenlogy 1994; 107: 1183-1188.
9. Bauer AK, Dwyer-Nield LD, Malkinson AM. High cyclooxygenase 1 (COX-1) and cyclooxygenase 2 (COX-2) contents in mouse lung tumors. Carcinogenesis 2000; 21: 543-550.
10. Chulada PC, Thompson MB, Mahler JF, Doyle CM, Gaul BW, Lee C et al. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 2000; 60: 4705-4708.
11. Gupta RA, Tejada LV, Tong BJ, Das SK, Morrow JD, Dey SK et al. Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res 2003; 63: 906-911.
12. Sales KJ, Katz AA, Howard B, Soeters RP, Millar RP, Jabbour HN. Cyclooxygenase-1 is up-regulated in cervical carcinomas: autocrine/paracrine regulation of cyclooxygenase-2, prostaglandin E receptors, and angiogenic factors by cyclooxygenase-1. Cancer Res 2002; 62: 424-432.
13. Hwang D, Scollard D, Byrne J, Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 1998; 90: 455-460.
14. Kirkpatrick K, Ogunkolade W, Elkak A, Bustin S, Jenkins P, Ghilchik M et al. The mRNA expression of cyclo-oxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) in human breast cancer. Curr Med Res Opin 2002; 18: 237-241.
15. Cianchi F, Cortesini C, Bechi P, Fantappie O, Messerini L, Vannacci A et al. Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterology 2001; 121: 1339-1347.
16. Su JL, Shih JY, Yen ML, Jeng YM, Chang CC, Hsieh CY et al. Cyclooxygenase-2 induces EP1- and HER-2/Neu-dependent vascular endothelial growth factor-C up-regulation: a novel mechanism of lymphangiogenesis in lung adenocarcinoma. Cancer Res 2004; 64: 554-564.
17. Murakami M, Nakashima K, Kamei D, Masuda S, Ishikawa Y, Ishii T et al. Cellular prostaglandin E2 production by membrane-bound prostaglandin E synthase-2 via both cyclooxygenases-1 and -2. J Biol Chem 2003; 278: 37937-37947.
18. Yoshimatsu K, Golijanin D, Paty PB, Soslow RA, Jakobsson PJ, DeLellis RA et al. Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer. Clin Cancer Res 2001; 7: 3971-3976.
19. de Caestecker MP, Piek E, Roberts AB. Role of transforming growth factor-beta signaling in cancer. J Natl Cancer Inst 2000; 92: 1388-1402.
20. Naef M, Ishiwata T, Friess H, Buchler MW, Gold LI, Korc M. Differential localization of transforming growth factor-beta isoforms in human gastric mucosa and overexpression in gastric carcinoma. Int J Cancer 1997; 71: 131-137.
21. Bellone G, Carbone A, Tibaudi D, Mauri F, Ferrero I, Smirne C et al. Differential expression of transforming growth factors-beta1, -beta2 and -beta3 in human colon carcinoma. Eur J Cancer 2001; 37: 224-233.
22. Han C, Demetris AJ, Liu Y, Shelhamer JH, Wu T. Transforming growth factor β (TGF-β) activates cytosolic phospholipase A2α (cPLA2α)-mediated prostaglandin E2 (PGE)2/EP1 and peroxisome proliferator-activated receptor-γ (PPAR-γ)/Smad signaling pathways in human liver cancer cells. A novel mechanism for subversion of TGF-β-induced mitoinhibition. J Biol Chem 2004; 279: 44344-44354.
23. Sobin LH, Wittekind C (eds). TNM Classification of Malignant Tumours (6th edn). Wiley-Liss: New York, 2002.
24. Hamilton SR, Aaltonen LA (eds). Pathology and Genetics of Tumours of the Digestive System. IARC Press: Lyons, 2000; 69-92.
25. Specht K, Richter T, Muller U, Walch A, Werner M, Hofler H. Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue. Am J Pathol 2001; 158: 419-429.
26. Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997; 57: 1276-1280.
27. Murata H, Kawano S, Tsuji S, Tsuji M, Sawaoka H, Kimura Y et al. Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma. Am J Gastroenterol 1999; 94: 451-455.
28. Walther Z. COX-2 and angiogenesis in gastric cancer. J Clin Gastroenterol 2003; 37: 4-6.
29. Shin VY, Wu WK, Ye YN, So WH, Koo MW, Liu ES et al. Nicotine promotes gastric tumor growth and neovascularization by activating extracellular signal-regulated kinase and cyclooxygenase-2. Carcinogenesis 2004; 25: 2487-2495.
30. Higuchi T, Iwama T, Yoshinaga K, Toyooka M, Taketo MM, Sugihara K. A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients. Clin Cancer Res 2003; 9: 4756-4760.
31. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 1946-1952.
32. Phillips RK, Wallace MH, Lynch PM, Hawk E, Gordon GB, Saunders BP et al. FAP Study Group. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 2002; 50: 857-860.
33. Altorki NK, Subbaramaiah K, Dannenberg AJ. COX-2 inhibition in upper aerodigestive tract tumors. Semin Oncol 2004; 31(Suppl 7): 30-36.
34. Onoda T, Ono T, Dhar DK, Yamanoi A, Fujii T, Nagasue N. Doxycycline inhibits cell proliferation and invasive potential: combination therapy with cyclooxygenase-2 inhibitor in human colorectal cancer cells. J Lab Clin Med 2004; 143: 207-216.
35. Nakata F, Mason KA, Hunter N, Husain A, Raju U, Liao Z et al. Potentiation of tumor response to radiation or chemoradiation by selective cyclooxygenase-2 enzyme inhibitors. Int J Radiat Oncol Biol Phys 2004; 58: 369-375.
36. Tuettenberg J, Grobholz R, Korn T, Wenz F, Erber R, Vajkoczy P. Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme. J Cancer Res Clin Oncol 2005; 131: 31-40.
37. Shinkaruk S, Bayle M, Lain G, Deleris G. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy. Curr Med Chem Anticancer Agents 2003; 3: 95-117.
38. Rosen LS. Angiogenesis inhibition in solid tumors. Cancer J 2001; 7(Suppl 3): S120-S128.
39. Schlaeppi JM, Wood JM. Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors. Cancer Metastasis Rev 1999; 18: 473-481.